Targeted drug combination therapy design based on driver genes.

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Targeted therapies for cancers with multiple driver genes offer promise but face challenges like drug availability and resistance to monotherapies.
• Simultaneous targeting of multiple driver genes across different pathways may overcome treatment resistance.

Purpose of the Study:

• To identify synergistic drug combinations for cancer treatment based on drug availability and biological activity.
• To evaluate the efficacy of customized, multi-driver gene-targeting combination therapies against cancer cell lines and primary cultures.

Main Methods:

• Created a compound library targeting driver gene-related proteins.
• Tested 55-102 drug combinations per cell line, focusing on driver genes and pathways.
• Assessed synergy and tumor cell eradication rates.

Main Results:

• Found 25-85% of tested drug combinations to be highly synergistic.
• Demonstrated that blocking 2-5 cancer pathways with 2-3 targeted drugs effectively eradicated tumor cells at low concentrations.
• Showed customized combination therapies were more effective than monotherapies in six cell lines and primary cultures.

Conclusions:

• Driver gene pattern-based customized combination therapies significantly enhance cancer treatment efficacy.
• Combining targeted drugs against multiple tumor-specific drivers can improve outcomes and overcome resistance.
• This approach holds potential for more effective cancer treatment strategies.